Active, not recruitingPhase 2NCT03428802

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Studying Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rutgers, The State University of New Jersey
Principal Investigator
Eugenia Girda, MD
Rutgers Cancer Institute of New Jersey
Intervention
Laboratory Biomarker Analysis(other)
Enrollment
21 enrolled
Eligibility
18 years · All sexes
Timeline
20182023

Study locations (2)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03428802 on ClinicalTrials.gov

Other trials for Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Additional recruiting or active studies for the same condition.

See all trials for Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

← Back to all trials